Galapagos NV
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
28 feb 2014 - 07:00
Statutory name
Galapagos NV
Title
Galapagos provides status update for GSK2586184 in GSK’s psoriasis, lupus, and ulcerative colitis clinical studies
Comments
Mechelen, Belgium; 28 February 2014 – Galapagos NV (Euronext: GLPG) announced today that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and ulcerative colitis.
GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ inflammation alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK up to €34M in additional milestones, plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.